Published in Arthritis Res Ther on July 19, 2010
Cyclin-dependent kinase 9 inhibition protects cartilage from the catabolic effects of proinflammatory cytokines. Arthritis Rheumatol (2014) 2.03
Progress in intra-articular therapy. Nat Rev Rheumatol (2013) 1.24
Sustained intra-articular delivery of IL-1RA from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis. Eur Cell Mater (2015) 0.92
Functional role of IL-22 in psoriatic arthritis. Arthritis Res Ther (2012) 0.89
Role of scintigraphy with ⁹⁹mTc-infliximab in predicting the response of intraarticular infliximab treatment in patients with refractory monoarthritis. Eur J Nucl Med Mol Imaging (2012) 0.80
Spondyloarthritis and inflammatory bowel disease. Comorbidity and treatment implications. Z Rheumatol (2013) 0.77
Vascular perfusion kinetics by contrast-enhanced ultrasound are related to synovial microvascularity in the joints of psoriatic arthritis. Clin Rheumatol (2015) 0.77
Psoriatic arthritis and psoriasis: differential diagnosis. Clin Rheumatol (2016) 0.76
Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clin Rheumatol (2015) 0.76
Efficacy of tocilizumab in a patient with refractory psoriatic arthritis. Clin Rheumatol (2014) 0.75
Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med (1968) 27.34
Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature (2006) 13.75
Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum (2006) 10.39
A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature (2008) 8.22
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 6.49
Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol (2009) 4.73
Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol (2009) 4.69
Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest (1992) 3.72
Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest (2003) 3.14
Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum (2007) 3.06
Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum (2005) 2.89
Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis (2004) 2.47
Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol (2008) 2.20
A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol (2007) 2.16
Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol (2001) 1.74
Patterns of cytokine production in psoriatic synovium. J Rheumatol (1998) 1.72
Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum (2009) 1.70
Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum (2000) 1.65
Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol (1997) 1.65
From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev (2008) 1.65
Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum (1993) 1.64
Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response. Arthritis Rheum (1987) 1.60
Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med (2008) 1.51
Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis (2006) 1.50
Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis (2000) 1.44
Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: a clinical randomized trial. Arthritis Rheum (2009) 1.40
Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol (2001) 1.40
Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis (2006) 1.39
Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis (2009) 1.39
Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. Arthritis Rheum (2009) 1.32
Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. J Rheumatol (2007) 1.30
Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum (2008) 1.28
Chemokines in joint disease: the key to inflammation? Ann Rheum Dis (2004) 1.20
Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis (2005) 1.12
Clues to pathogenesis of spondyloarthropathy derived from synovial fluid mononuclear cell gene expression profiles. J Rheumatol (2002) 1.12
Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford) (2006) 1.11
The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis (2007) 1.10
Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum (2010) 1.10
Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol (2008) 1.09
Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther (2009) 1.09
Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol (2008) 1.07
Rheumatoid and psoriatic knee synovitis: clinical, grey scale, and power Doppler ultrasound assessment of the response to etanercept. Ann Rheum Dis (2004) 1.06
Should we be using intraarticular tumor necrosis factor blockade in inflammatory monoarthritis? J Rheumatol (2006) 1.02
Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis. Rheumatol Int (2000) 0.97
Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum (2005) 0.96
A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann Rheum Dis (2008) 0.95
Interleukin-17 gene expression in patients with rheumatoid arthritis. Mod Rheumatol (2007) 0.94
Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade. Ann Rheum Dis (2009) 0.92
Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective. Curr Rheumatol Rep (2004) 0.91
Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. J Rheumatol (2009) 0.91
Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. Autoimmun Rev (2007) 0.91
Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis (2006) 0.90
High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis. Clin Exp Rheumatol (2009) 0.85
A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. Scand J Rheumatol (2006) 0.85
Value of synovial fluid interleukin-1 beta determination in predicting the outcome of psoriatic monoarthritis. Ann Rheum Dis (1996) 0.83
Effectiveness of psoriatic arthritis therapies. Semin Arthritis Rheum (2003) 0.83
Localized monocyte chemotactic protein-1 production correlates with T cell infiltration of synovium in patients with psoriatic arthritis. J Rheumatol (2000) 0.83
Assessment tools in psoriatic arthritis. J Rheumatol (2008) 0.78
Biological biomarkers in psoriatic disease. A review. J Rheumatol (2008) 0.77
Translational perspectives on psoriatic arthritis. J Rheumatol Suppl (2009) 0.76
The relationship between serum-soluble interleukin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporin-A. Rheumatol Int (1998) 0.76
Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity (2010) 3.88
Identification of a central role for complement in osteoarthritis. Nat Med (2011) 3.11
A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J (2007) 2.76
Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax (2010) 2.60
Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a randomized controlled trial. J Rheumatol (2011) 2.45
Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation. Crit Care Med (2004) 2.33
Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation (2003) 2.12
Concealed metastatic lung carcinoma presenting as acute coronary syndrome with progressive conduction abnormalities. Circulation (2012) 2.10
Autophagy in human health and disease. N Engl J Med (2013) 2.04
Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood (2008) 1.91
Gout: why is this curable disease so seldom cured? Ann Rheum Dis (2012) 1.84
Pathology of pulmonary antibody-mediated rejection: 2012 update from the Pathology Council of the ISHLT. J Heart Lung Transplant (2013) 1.71
Nonatopic children with multitrigger wheezing have airway pathology comparable to atopic asthma. Am J Respir Crit Care Med (2008) 1.67
Noninvasive ventilation in mild obesity hypoventilation syndrome: a randomized controlled trial. Chest (2011) 1.65
Epithelial damage and angiogenesis in the airways of children with asthma. Am J Respir Crit Care Med (2006) 1.58
Contrast-enhanced ultrasound for characterizing lymph nodes with focal cortical thickening in patients with cutaneous melanoma. AJR Am J Roentgenol (2011) 1.55
Immune activation in α1-antitrypsin-deficiency emphysema. Beyond the protease-antiprotease paradigm. Am J Respir Crit Care Med (2015) 1.52
Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J Immunol (2003) 1.51
Acute rejection and graft survival in renal transplanted patients with viral diseases. Mod Pathol (2004) 1.51
Receptor activator of NF- κB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. Thromb Haemost (2011) 1.48
Serum amyloid-A in Behçet's disease. Clin Rheumatol (2014) 1.47
Heterotopic cardiac xenotransplantation in rodents: report of a refined technique in a hamster-to-rat model. Microsurgery (2005) 1.47
Acute biopsy-proven lymphocytic myocarditis mimicking Takotsubo cardiomyopathy. Eur J Heart Fail (2009) 1.44
Expression and role of CCR6/CCL20 chemokine axis in pulmonary sarcoidosis. J Leukoc Biol (2007) 1.37
The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase. Cell Metab (2013) 1.36
Arrhythmogenic right ventricular cardiomyopathy causing sudden cardiac death in boxer dogs: a new animal model of human disease. Circulation (2004) 1.33
IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 1.31
Deficient antiviral immune responses in childhood: distinct roles of atopy and asthma. J Allergy Clin Immunol (2012) 1.28
Hyperforin inhibits cancer invasion and metastasis. Cancer Res (2004) 1.27
Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep (2013) 1.25
2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol (2011) 1.24
Airway inflammation in childhood asthma. Am J Respir Crit Care Med (2003) 1.21
Role for CXCR6 and its ligand CXCL16 in the pathogenesis of T-cell alveolitis in sarcoidosis. Am J Respir Crit Care Med (2005) 1.19
Resistant Behçet disease responsive to anakinra. Ann Intern Med (2008) 1.15
Autoantibodies against protective molecules--C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N Y Acad Sci (2007) 1.15
OARSI/OMERACT initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. An OMERACT 10 Special Interest Group. J Rheumatol (2011) 1.14
Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum (2002) 1.10
Erosive osteoarthritis. Best Pract Res Clin Rheumatol (2004) 1.10
Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients. Nephrol Dial Transplant (2009) 1.06
Overlap connective tissue disease syndromes. Autoimmun Rev (2012) 1.05
Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J (2011) 1.05
Randomized trial of the effect of antipyresis by metamizol, propacetamol or external cooling on metabolism, hemodynamics and inflammatory response. Intensive Care Med (2004) 1.05
Pregnancy, cytokines, and disease activity in systemic lupus erythematosus. Arthritis Rheum (2004) 1.04
Functional VEGF and VEGF receptors are expressed in human medulloblastomas. Neuro Oncol (2007) 1.04
Contrast medium in power Doppler ultrasound for assessment of synovial vascularity: comparison with arthroscopy. J Rheumatol (2003) 1.02
Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra. Joint Bone Spine (2010) 1.02
Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease. PLoS One (2013) 1.01
Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets. Autoimmun Rev (2012) 1.00
Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer (2005) 1.00
SERPINB3 induces epithelial-mesenchymal transition. J Pathol (2010) 1.00
Blau syndrome, clinical and genetic aspects. Autoimmun Rev (2012) 0.99
Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. Ann Rheum Dis (2012) 0.99
The potential role of bone scintigraphy in the detection of deep muscular fascia involvement and calcinosis cutis in anti-synthetase syndrome. Int J Rheum Dis (2013) 0.98
Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol (2012) 0.98
Dermatomyositis and malignancy of the pharynx in Caucasian patients: report of two observations. Rheumatol Int (2003) 0.97
Profile of circulating cytokines: impact of OSA, obesity and acute cardiovascular events. Cytokine (2013) 0.97
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr Relat Cancer (2010) 0.97
Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum (2010) 0.97
A novel insight into adaptive immunity in chronic obstructive pulmonary disease: B cell activating factor belonging to the tumor necrosis factor family. Am J Respir Crit Care Med (2010) 0.96
Successful resection of a giant primary liposarcoma of the posterior mediastinum. J Thorac Oncol (2007) 0.95
International position paper on febuxostat. Clin Rheumatol (2010) 0.95
Endomyocardial fibrosis: pathological and molecular findings of surgically resected ventricular endomyocardium. Virchows Arch (2008) 0.95
Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol (2014) 0.94
Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol (2013) 0.94
Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. Rheumatology (Oxford) (2013) 0.94
Expression of the atypical chemokine receptor D6 in human alveolar macrophages in COPD. Chest (2013) 0.93
Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediators Inflamm (2013) 0.93
Endothelial dysfunction and specific inflammation in obesity hypoventilation syndrome. PLoS One (2009) 0.93
Do results of the T-SPOT.TB interferon-gamma release assay change after treatment of tuberculosis? Respir Med (2008) 0.93
Serpins, immunity and autoimmunity: old molecules, new functions. Clin Rev Allergy Immunol (2013) 0.93
Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. J Rheumatol (2002) 0.93
Anakinra treatment in drug-resistant Behcet's disease: a case series. Clin Rheumatol (2013) 0.92
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev (2012) 0.92
Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. Immunol Res (2013) 0.92
The role of preoperative ultrasound scan in detecting lymph node metastasis before sentinel node biopsy in melanoma patients. J Surg Oncol (2003) 0.92
Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade. Ann Rheum Dis (2009) 0.92
New biochemical insights into the pathogenesis of osteoarthritis and the role of laboratory investigations in clinical assessment. Crit Rev Clin Lab Sci (2005) 0.91
Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin Exp Rheumatol (2012) 0.91
HDL interfere with the binding of T cell microparticles to human monocytes to inhibit pro-inflammatory cytokine production. PLoS One (2010) 0.91
Successful treatment of enterovirus-induced myocarditis with interferon-alpha. J Heart Lung Transplant (2003) 0.91
The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J (2011) 0.91
SERPINB3 modulates TGF-beta expression in chronic liver disease. Lab Invest (2010) 0.91
Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept. Autoimmun Rev (2008) 0.91